Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v2.4.0.8
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2014
Fair Value Measurements Tables  
Financial instruments carried at fair value on a recurring
          Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description   June 30, 2014     (Level 1)     (Level 2)     (Level 3)  
Assets:                        
Cash and cash equivalents   $ 4,074     $ 4,074     $ -     $ -  
Marketable securities     5,719       -       5,719       -  
Total assets   $ 9,793     $ 4,074     $ 5,719     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 6,450     $ -     $ -     $ 6,450  
Total liabilities   $ 6,450     $ -     $ -       6,450  
                                 
    December 31, 2013     Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description       (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 1,034     $ 1,034     $ -     $ -  
Total assets   $ 1,034     $ 1,034     $ -       -  
                                 
Liabilities:                                
Derivative liability   $ 23     $ -     $ -     $ 23  
Total liabilities   $ 23     $ -     $ -       23  
Level 3 financial assets and liabilities
    Fair Value Measurements Using Significant Unobservable Inputs  
    (Level 3)  
Balance, January 1, 2014   $ 23  
Change in fair value of Teva option     (23 )
Estimated fair value of warrants assumed in merger on January 2, 2014     10,475  
Estimated fair value of warrants issued in January common stock sale     3,696  
Change in fair value of warrants for the period ended June 30, 2014     (7,721 )
Balance at June 30, 2014   $ 6,450